MedTrace Logo

Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).

NCT05010876 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-12-22

No results posted yet for this study

Summary

The main objective of this study is to evaluate the efficacy of human C1 inhibitor, administered alone or in combination with icatibant (a specific bradykinin B2 receptor antagonist) on the pulmonary manifestations of COVID-19 infections.

Conditions

  • Covid19

Interventions

DRUG

C1 Inhibitor Human

standard care + 1000 units of C1 inhibitor during 2 slow infusions of 500 units

DRUG

Icatibant Injection

a single injection of 30 mg subcutaneously

OTHER

Placebo

The placebo will be physiological serum presented in forms mimicking the C1-Inhibitor and the icatibant.

Sponsors & Collaborators

  • GCS Ramsay Santé pour l'Enseignement et la Recherche

    lead OTHER

Principal Investigators

  • Denis VINCENT, MD PD · Médecine interne, Faculté de Montpellier

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-04
Primary Completion
2021-06-13
Completion
2021-06-21

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05010876 on ClinicalTrials.gov